News

Fujifilm Diosynth in ADC Alliance
Enlarge image

PharmaUK

Fujifilm Diosynth in ADC Alliance

25.10.2012 - Fujifilm Diosynth has partnered with British Piramal Healthcare to produce Antibody Drug Conjugates.

Fujifilm Diosynth Biotechnologies has entered into a strategic alliance with Piramal Healthcare UK Ltd (Billingham, UK) in the emerging market of antibody drug conjugates (ADCs), that is antibodies chemically coupled to a small molecule toxin. Under the terms of the contract development and manufacture agreement, Piramal will bring in its expertise in antibody drug conjugation while Fujifilm Diosynth Biotechnologies will provide its experience in manufacturing biopharmaceuticals in mammalian cell culture. The companies said the deal will allow customers to benefit from the experience and assets of both organisations, while simplifying the supply chain and vendor management relationships, leading to shorter time to clinic.

The partnership covers work on more than 150 biopharmaceuticals and over 300 batches of ADCs spanning over more than 30 different NCEs, including the world's only FDA-approved ADC, Seattle Genetics’ Adcetris. Fujifilm Diosynth Biotechnologies recently announced an expansion of its cGMP manufacturing facilities at both its RTP, USA and Billingham, UK sites.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/fujifilm-diosynth-in-adc-alliance.html

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.65 EUR6.00%
  • FORMYCON10.90 EUR4.51%
  • CYTOS0.29 CHF3.57%

FLOP

  • BIOTEST79.48 EUR-2.68%
  • ADDEX2.99 CHF-1.97%
  • EVOTEC3.23 EUR-1.22%

TOP

  • CYTOS0.29 CHF70.6%
  • FORMYCON10.90 EUR38.1%
  • EPIGENOMICS5.16 EUR35.8%

FLOP

  • 4SC0.90 EUR-15.1%
  • CO.DON2.65 EUR-9.6%
  • BIOFRONTERA2.59 EUR-9.4%

TOP

  • SANTHERA92.95 CHF2346.1%
  • CO.DON2.65 EUR165.0%
  • BB BIOTECH183.40 EUR61.4%

FLOP

  • CYTOS0.29 CHF-91.3%
  • 4SC0.90 EUR-49.4%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 26.11.2014